Compare BNR & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNR | SGHT |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | China | United States |
| Employees | 674 | N/A |
| Industry | Medical Specialities | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.7M | 282.9M |
| IPO Year | 2019 | 2021 |
| Metric | BNR | SGHT |
|---|---|---|
| Price | $22.81 | $3.71 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.08 |
| AVG Volume (30 Days) | 13.1K | ★ 351.0K |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $77,363,000.00 |
| Revenue This Year | $136.32 | $13.54 |
| Revenue Next Year | N/A | $14.53 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.18 | $2.03 |
| 52 Week High | $41.72 | $9.24 |
| Indicator | BNR | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 40.95 | 29.33 |
| Support Level | $7.99 | $3.26 |
| Resistance Level | $24.23 | $4.33 |
| Average True Range (ATR) | 2.07 | 0.35 |
| MACD | -0.41 | -0.11 |
| Stochastic Oscillator | 29.88 | 5.80 |
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.